Article Text

Download PDFPDF
High-dose medroxyprogesterone acetate in advanced ovarian cancer
  1. M. A. Quinn,
  2. R. M. Rome,
  3. P. Grant and
  4. R. S. Planner
  1. Royal Women's Hospital and Mercy Hospital, Melbourne, Australia
  1. Address for correspondence: Department of Gynecologic Oncology, Royal Women's Hospital, Grattan Street, Carlton, Victoria, 3053 Australia.


Seventeen patients with advanced ovarian malignancy were treated with high-dose medroxyprogesterone acetate. No objective responses were achieved. Four patients had stable disease, one of whom remains alive with disease at 30+ months.

  • hormone therapy
  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.